1. Home
  2. IMTE vs AEMD Comparison

IMTE vs AEMD Comparison

Compare IMTE & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integrated Media Technology Limited

IMTE

Integrated Media Technology Limited

HOLD

Current Price

$0.45

Market Cap

2.0M

ML Signal

HOLD

Logo Aethlon Medical Inc.

AEMD

Aethlon Medical Inc.

HOLD

Current Price

$0.89

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMTE
AEMD
Founded
2008
1984
Country
Australia
United States
Employees
N/A
9
Industry
Consumer Electronics/Appliances
Medical/Dental Instruments
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
2.1M
IPO Year
2016
2008

Fundamental Metrics

Financial Performance
Metric
IMTE
AEMD
Price
$0.45
$0.89
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$15.00
AVG Volume (30 Days)
55.2K
316.9K
Earning Date
10-22-2024
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.40
$0.51
52 Week High
$1.54
$5.89

Technical Indicators

Market Signals
Indicator
IMTE
AEMD
Relative Strength Index (RSI) 45.30 24.61
Support Level $0.43 $0.51
Resistance Level $0.57 $2.47
Average True Range (ATR) 0.07 0.19
MACD -0.01 -0.12
Stochastic Oscillator 18.88 5.29

Price Performance

Historical Comparison
IMTE
AEMD

About IMTE Integrated Media Technology Limited

Integrated Media Technology Ltd is mainly engaged in the business of manufacture and sale of nano-coated plates for filters, the manufacture and sale of electronic glass, Halal certification and distribution of Halal products, and new energy products and services. It operates through the following segments: the sale of electronic glass, sales of air-filter products, sales of Halal products, NFT, corporate, provision of consultancy and provision of new energy products and solutions.

About AEMD Aethlon Medical Inc.

Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.

Share on Social Networks: